- Home
- ROIV vs TLN Comparison
ROIV vs TLN Comparison
Compare ROIV & TLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- TLN
- Stock Information
- Founded
- ROIV 2014
- TLN 2015
- Country
- ROIV United Kingdom
- TLN United States
- Employees
- ROIV N/A
- TLN N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- TLN Electric Utilities: Central
- Sector
- ROIV Health Care
- TLN Utilities
- Exchange
- ROIV Nasdaq
- TLN Nasdaq
- Market Cap
- ROIV 8.4B
- TLN 9.7B
- IPO Year
- ROIV N/A
- TLN N/A
- Fundamental
- Price
- ROIV $10.64
- TLN $225.16
- Analyst Decision
- ROIV Buy
- TLN Strong Buy
- Analyst Count
- ROIV 4
- TLN 11
- Target Price
- ROIV $17.50
- TLN $241.36
- AVG Volume (30 Days)
- ROIV 6.2M
- TLN 798.1K
- Earning Date
- ROIV 05-29-2025
- TLN 05-08-2025
- Dividend Yield
- ROIV N/A
- TLN N/A
- EPS Growth
- ROIV N/A
- TLN 66.23
- EPS
- ROIV N/A
- TLN 10.79
- Revenue
- ROIV $122,585,000.00
- TLN $1,954,000,000.00
- Revenue This Year
- ROIV N/A
- TLN $13.51
- Revenue Next Year
- ROIV N/A
- TLN $17.42
- P/E Ratio
- ROIV N/A
- TLN $20.85
- Revenue Growth
- ROIV 140.04
- TLN N/A
- 52 Week Low
- ROIV $8.73
- TLN $98.50
- 52 Week High
- ROIV $13.06
- TLN $258.03
- Technical
- Relative Strength Index (RSI)
- ROIV 47.30
- TLN 58.52
- Support Level
- ROIV $11.02
- TLN $216.20
- Resistance Level
- ROIV $11.77
- TLN $242.60
- Average True Range (ATR)
- ROIV 0.33
- TLN 9.02
- MACD
- ROIV -0.02
- TLN 1.98
- Stochastic Oscillator
- ROIV 28.93
- TLN 63.72
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About TLN Talen Energy Corporation Common Stock
Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.